Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: Jefferson Research
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sangamo Biosciences Inc gives FY 2014 revenue guidance above analysts' estimates

Tuesday, 11 Feb 2014 04:05pm EST 

Sangamo Biosciences Inc:Expects that revenues will be in the range of $45 million to $50 million in fiscal 2014, inclusive of research funding and certain milestone payments from Shire and Biogen.Fiscal 2014 revenue of $35 million - Thomson Reuters I/B/E/S. 

Company Quote

0.18 +1.28%
29 Aug 2014